Drug-Device Combinations in Dermatology: Integrating Pharmaceuticals with Advanced Cosmetic Technologies

Background: A paradigm shift is brought about by the combination of medicines with cutting-edge medical technology, which improves patient outcomes, effectiveness, and accuracy. The review dives into applications such as anti-aging therapy, nanotechnology, and acne treatment while also examining obstacles, traditional procedures, and current breakthroughs. It highlights the difficulties with patient adherence, safety, and regulatory barriers while projecting a future where genetics, biosensors, and artificial intelligence will power tailored therapies. Emphasis is placed on the potential for global dermatological health, imagining a time when drugdevice combos would alter skincare globally. Objectives: This study aims to provide a comprehensive overview of the current landscape of drug-device combinations in dermatology and advancement in drug-device combinations for dermatological therapy. Methods: A literature search was performed on PubMed and Google Scholar using the following key terms” Dermatology,” “Cosmetic technologies,” “Dermatopharmacology,” “Beauty Perception,” and “Skincare.” Result: The assessment of the safety and effectiveness profiles of various drug-device combinations, considering long-term effects, adverse events, patient satisfaction, and clinical results. This includes an examination of the fundamental processes by which pharmaceuticals and cuttingedge cosmetic technologies work together to produce therapeutic outcomes like improved drug delivery, targeted therapy, and synergistic effects. Conclusion: In conclusion, drug-device combinations offer a viable way to improve therapeutic outcomes and elevate patient care in dermatology by fusing pharmaceuticals with cutting-edge cosmetic technology. Our analysis focuses on the wide range of combinations that are currently available, as well as their effectiveness, safety profiles, and underlying mechanisms of action. Even though there has been a lot of development, issues, including patient variability, technical constraints, and regulatory barriers, still exist.